Sentences with phrase «aggressive prostate cancer in»

An epidemiological study of people in Northern Italy reported that vitamin C intake has «possible protective activity» against skin cancer202 and greater consumption of antioxidants was associated with less aggressive prostate cancer in the United States.203 A 2014 systematic review by Chinese researchers concluded that low doses of vitamins, specifically vitamins A, C and E, can significantly reduce the risk of stomach cancer.204

This resulted in a higher absolute number of aggressive prostate cancers in the dutasteride group than in the placebo group — even though the placebo group had a higher rate of prostate cancer.141 Thus, as we have seen elsewhere, e.g., rofecoxib (Vioxx ®), celecoxib (Celebrex ®), balance in biological processes is more beneficial than absolute interruption.)

This resulted in a higher absolute number of aggressive prostate cancers in the dutasteride group than in the placebo group — even though the placebo group had a higher rate of prostate cancer.145 (See above «Mechanisms through which 5α - reductase inhibitors promote prostate cancer»)(Neal, please make this a link to this section above) Thus, as we have seen elsewhere, e.g., rofecoxib (Vioxx ®), celecoxib (Celebrex ®), balance in biological processes is more beneficial than absolute interruption.)

Not exact matches

«Markers for prostate cancer death can identify men in need of more aggressive treatment.»

Eating a diet higher in saturated fat, a type of fat found commonly in foods such as fatty beef and cheese, was linked to more aggressive prostate cancer, a study by University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators has cancer, a study by University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators has Cancer Center researchers and collaborators has found.

«Genetic association with aggressive prostate cancer discovered: Study showed a threefold increase in the risk of aggressive prostate cancer for men with the genetic mutation..»

An international study published in the Journal of the National Cancer Institute has identified a genetic connection to the aggressive form of prostate cCancer Institute has identified a genetic connection to the aggressive form of prostate cancercancer.

«Why prostate cancer is more aggressive in obese patients.»

In a new study published in The Journal of Urology ®, researchers determined that men who followed a Mediterranean diet, rich in fish, boiled potatoes, whole fruits, vegetables, legumes, and olive oil, and low consumption of juices had lower risk of aggressive prostate cancer (PC) than those who followed other dietary patterns like Prudent or Western dietIn a new study published in The Journal of Urology ®, researchers determined that men who followed a Mediterranean diet, rich in fish, boiled potatoes, whole fruits, vegetables, legumes, and olive oil, and low consumption of juices had lower risk of aggressive prostate cancer (PC) than those who followed other dietary patterns like Prudent or Western dietin The Journal of Urology ®, researchers determined that men who followed a Mediterranean diet, rich in fish, boiled potatoes, whole fruits, vegetables, legumes, and olive oil, and low consumption of juices had lower risk of aggressive prostate cancer (PC) than those who followed other dietary patterns like Prudent or Western dietin fish, boiled potatoes, whole fruits, vegetables, legumes, and olive oil, and low consumption of juices had lower risk of aggressive prostate cancer (PC) than those who followed other dietary patterns like Prudent or Western diets.

But although the drug, called finasteride, caused a 25 % reduction in prostate cancer, it also boosted the risk of aggressive prostate cancer among those diagnosed with the disease.

«A more complete Mediterranean diet may protect against aggressive prostate cancer: New study in The Journal of Urology ® finds that a high intake of fruits, vegetables, and whole grains might not be enough.»

Of greater concern were the higher rates of prostate cancer classified as aggressive: It developed in 6.4 % of the men in the finasteride group, compared with 5.1 % in the placebo group.

A Northwestern University - led study in the emerging field of nanocytology could one day help men make better decisions about whether or not to undergo aggressive prostate cancer treatments.

«Emotional distress may motivate men with low - risk prostate cancer to choose more aggressive treatment, such as choosing surgery over active surveillance,» said UB's Heather Orom, the lead author on the study, published in the February issue of the Journal of Urology.

In the group of patients with aggressive, or high risk, prostate cancer, the average number of days from diagnosis to surgery or radiation treatment was 96 days for Caucasian patients, and 105 days for African American patients.

The authors stressed that the long - term reduction in aggressive disease was observed only in men after more than a year of testosterone use, and the risk of prostate cancer did not differ between gels and other types of preparations.

In the study, researchers found that, as a group, men prescribed testosterone for longer than a year had no overall increase in risk of prostate cancer and, in fact, had their risk of aggressive disease reduced by 50 percenIn the study, researchers found that, as a group, men prescribed testosterone for longer than a year had no overall increase in risk of prostate cancer and, in fact, had their risk of aggressive disease reduced by 50 percenin risk of prostate cancer and, in fact, had their risk of aggressive disease reduced by 50 percenin fact, had their risk of aggressive disease reduced by 50 percent.

The old idea that cancer is less aggressive in the elderly is not entirely without merit: breast and prostate cancers tend to grow more slowly in older patients.

Researchers have discovered that a marker found on aggressive prostate cancer cells could also be used as a way to guide treatments to the cancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Livecancer cells could also be used as a way to guide treatments to the cancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Livecancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in LiveCancer Research Institute (NCRI) Cancer Conference in LiveCancer Conference in Liverpool.

«These genes are found in between 6 and 14 % of men» said Alexandre Zlotta, «This makes it one of, if not the, most common genes yet found to be associated with aggressive prostate cancer.

The new technology led to the diagnosis of an aggressive prostate cancer located in an area normally not visible using the ultrasound machine alone.

«In some cases, a low volume of less aggressive prostate cancer may not necessitate treatment, but even in those cases where a «treatment» is not performed in favor of active surveillance, the emotional distress of a cancer diagnosis shouldn't be underestimated,» Turini saiIn some cases, a low volume of less aggressive prostate cancer may not necessitate treatment, but even in those cases where a «treatment» is not performed in favor of active surveillance, the emotional distress of a cancer diagnosis shouldn't be underestimated,» Turini saiin those cases where a «treatment» is not performed in favor of active surveillance, the emotional distress of a cancer diagnosis shouldn't be underestimated,» Turini saiin favor of active surveillance, the emotional distress of a cancer diagnosis shouldn't be underestimated,» Turini said.

In addition, research continues to uncover new clues to identify which men are at highest risk of aggressive prostate cancer and could most benefit from screening and treatment.

'' (In the context of prostate cancer) there's a big interest in trying to find biomarkers to discriminate between aggressive and nonaggressive disease,» said Renny Franceschi, U-M professor of dentistry, biological chemistry and biomedical engineerinIn the context of prostate cancer) there's a big interest in trying to find biomarkers to discriminate between aggressive and nonaggressive disease,» said Renny Franceschi, U-M professor of dentistry, biological chemistry and biomedical engineerinin trying to find biomarkers to discriminate between aggressive and nonaggressive disease,» said Renny Franceschi, U-M professor of dentistry, biological chemistry and biomedical engineering.

A new study published online by Science links chronic fatigue syndrome to a possibly contagious rodent retrovirus, XMRV, which has also been implicated in an aggressive form of prostate cancer.

In unrelated studies, other researchers have linked XMRV — again controversially — to an aggressive form of prostate cancer.

As if chronic fatigue syndrome (CFS) hasn't caused enough brawls, a new study published online by Science links the disease to a possibly contagious rodent retrovirus, XMRV, which has also been implicated in an aggressive form of prostate cancer.

Like pervasive hypertension, some cancers, such as prostate and breast, tend to occur earlier and be more aggressive in blacks than whites, said Dr. Edward J. Kruse, chief of surgical oncology at MCG and the Georgia Cancer Center.

The latest studies suggest that a man's BRCA status can be an important piece of information, especially at a time when many doctors are taking a less aggressive stance in screening and treating prostate cancer.

PSMA is overexpressed in prostate and increases in its expression in the aggressive forms of prostate cancer.

Mutations in the beta - catenin gene, or flaws in the factors that degrade it, have long been linked to more aggressive disease in various tumor types, including colon, lung and prostate cancer, and melanoma.

Carriers of germline mutations in BRCA2 have at least five times greater risk of prostate cancer and frequently develop a more aggressive form of the disease.

Professor Ros Eeles from the Institute of Cancer Research and The Royal Marsden, who co-leads the prostate cancer ICGC study with Professor Colin Cooper from the ICR and Professors David Neal and Douglas Easton from The University of Cambridge, said: «One of the major challenges in treating prostate cancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop quCancer Research and The Royal Marsden, who co-leads the prostate cancer ICGC study with Professor Colin Cooper from the ICR and Professors David Neal and Douglas Easton from The University of Cambridge, said: «One of the major challenges in treating prostate cancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop qucancer ICGC study with Professor Colin Cooper from the ICR and Professors David Neal and Douglas Easton from The University of Cambridge, said: «One of the major challenges in treating prostate cancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop qucancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop quickly.

Men who carry heterozygous deleterious germline mutations in BRCA2 are predisposed to aggressive prostate cancer (1 — 4).

I think we all agree that we over treat prostate cancer in this country compared to what you see in Europe with similar outcomes and so but I think this is where the human or the Cancer Genome Project or at least better biomarkers for looking at mutations that we already know occur in these diseases I think hopefully within the next few years every single patient who is diagnosed with prostate cancer those biopsies will be characterized and then the patients followed, hopefully watchful waiting and we'll ultimately get a correlation between what mutational events predict a rather dormant disease as opposed to a very aggressive dicancer in this country compared to what you see in Europe with similar outcomes and so but I think this is where the human or the Cancer Genome Project or at least better biomarkers for looking at mutations that we already know occur in these diseases I think hopefully within the next few years every single patient who is diagnosed with prostate cancer those biopsies will be characterized and then the patients followed, hopefully watchful waiting and we'll ultimately get a correlation between what mutational events predict a rather dormant disease as opposed to a very aggressive diCancer Genome Project or at least better biomarkers for looking at mutations that we already know occur in these diseases I think hopefully within the next few years every single patient who is diagnosed with prostate cancer those biopsies will be characterized and then the patients followed, hopefully watchful waiting and we'll ultimately get a correlation between what mutational events predict a rather dormant disease as opposed to a very aggressive dicancer those biopsies will be characterized and then the patients followed, hopefully watchful waiting and we'll ultimately get a correlation between what mutational events predict a rather dormant disease as opposed to a very aggressive disease.

Research shows how signaling by an immune system component appears to play an important role in driving particularly aggressive prostate cancer...

Roswell Park Cancer Institute researchers have identified a gene that influences metastasis in prostate cancer, and may help clinicians to identify aggressive prostate tumors before they progress and spread to other oCancer Institute researchers have identified a gene that influences metastasis in prostate cancer, and may help clinicians to identify aggressive prostate tumors before they progress and spread to other ocancer, and may help clinicians to identify aggressive prostate tumors before they progress and spread to other organs.

Leigh Ellis, PhD, and colleagues at Roswell Park Comprehensive Cancer Center (Roswell Park) have identified two genes that appear to be simultaneously overexpressed in aggressive prostate cancers resistant to the androgen - targeted treatments enzalutamide and abiraterone acetate.

His laboratory is interested in understanding the role of metabolic adaptations in breast and prostate cancer progression, and elucidating mechanisms that promote therapy resistant aggressive metastatic disease.

A study was done in 2013 which proved that patients who had poor sleeping habits were much more likely to develop an aggressive form of prostate cancer.

While men with the more aggressive form of the cancer make up about 5 % of the 180,000 to 200,000 cases of prostate cancer in the U.S. each year, and only 12 % will have these mutations, that population is still at considerably higher risk of developing advanced disease.

In a report published in the New England Journal of Medicine, scientists say that a panel of 20 genes can distinguish the more common localized prostate cancer that grows slowly and rarely spreads from the more aggressive type that can spread quicklIn a report published in the New England Journal of Medicine, scientists say that a panel of 20 genes can distinguish the more common localized prostate cancer that grows slowly and rarely spreads from the more aggressive type that can spread quicklin the New England Journal of Medicine, scientists say that a panel of 20 genes can distinguish the more common localized prostate cancer that grows slowly and rarely spreads from the more aggressive type that can spread quickly.

The findings also hint that in coming years, it may be possible to use the panel not just among men with advanced disease but to distinguish between men who develop the slower growing type of prostate cancer from the more aggressive type.

Considering the side effects and adverse results of prostate cancer treatment, these new results may help some men make the choice to forgo aggressive treatment in lieu of less invasive options.

The task force also calls for more research in this area, including ongoing studies looking at the potential for MRI and genetic testing to better detect aggressive prostate cancers, Krist added.

In the Prostate Cancer Prevention Trial, a study involving more than 18,000 men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebProstate Cancer Prevention Trial, a study involving more than 18,000 men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebo Cancer Prevention Trial, a study involving more than 18,000 men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebprostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebo cancer, but a significantly higher rate of aggressive prostate cancers than the placebprostate cancers than the placebo group.

However, recent studies show a correlation between low levels of DHT and decreased survival in prostate cancer patients, rendering this assumption highly questionable.16, 17, 18, 19 According to one recent paper, «Low dihydrotestosterone in the prostate is probably sufficient to propagate the growth of aggressive prostate cancer.»

In the Prostate Cancer Prevention Trial, a study involving more than eighteen thousand men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebProstate Cancer Prevention Trial, a study involving more than eighteen thousand men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebo Cancer Prevention Trial, a study involving more than eighteen thousand men, subjects taking dutasteride had a lower rate of prostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebprostate cancer, but a significantly higher rate of aggressive prostate cancers than the placebo cancer, but a significantly higher rate of aggressive prostate cancers than the placebprostate cancers than the placebo group.

But then a friend was diagnosed with a very aggressive form of prostate cancer and I got involved in helping rehab his pelvic floor through what I knew from teaching women.

Not to mention that fish oil could result in «aggressive» prostate cancer.